FDA approves Alzheimer's drug shown to slow decline in memory, cognition in those with the disease

The U.S. Food and Drug Administration has approved an Alzheimer's drug that's been proven to slow memory and cognitive decline in patients with the disease.

The body naturally produces the protein amyloid, but when it clumps together to create amyloid plaques, an excessive buildup can affect bodily organs and tissue. And in the brain, that leads to memory and cognitive issues that are associated with Alzheimer's disease. Participants in the Kisunla trial saw an average reduction in amyloid plaques by 61% at six months and 80% at 12 months. Eighteen months after the start of the trial, the buildup was 84% reduced, and the once-monthly infusions were shown to have slowed cognitive and functional decline by up to 35% compared to the placebo. Up to 39% of participants also saw a reduced risk in progressing to the next clinical stage of the disease.

The cost of Kisunla will vary depending on the patient and the length of their treatment period, but Medicare is expected to provide coverage. Eli Lilly does have a free support program that can help patients determine their coverage assistance and coordinate care, found at Kisunla.Lilly.com.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Source: KSLcom - 🏆 549. / 51 Read more »

FDA advisors recommend Eli Lilly Alzheimer’s drug that slows diseaseEli Lilly's new Alzheimer's drug, donanemab, received approval from an advisory panel for the FDA. The full agency is expected to approve the drug by spring.
Source: dcexaminer - 🏆 6. / 94 Read more »

Alzheimer’s drug from Eli Lilly wins backing of FDA committeeAn advisory committee to the Food and Drug Administration found the drug was safe and effective at slowing the progression of the disease, setting the stage for the agency to approve it.
Source: washingtonpost - 🏆 95. / 72 Read more »

FDA approves new Alzheimer's treatment, donanemab from Eli LillyFDA approval of the new Alzheimer's treatment, which will be branded as Kisunla, follows years of setbacks.
Source: CBSNews - 🏆 87. / 68 Read more »